Author: -Novadmin7819

Novaptech: new offices!

Inauguration of the brand new premises of Novaptech, a leading biotechnology company producing aptamers for the detection of contaminants in the food industry Novaptech, an innovative biotechnology company, inaugurated its new premises in Gradignan on May 31st, 2024, in the presence of Mr Alain Rousset, President of the Conseil Régional de Nouvelle-Aquitaine. Created in 2016 from Jean-Jacques Toulmé’s academic laboratory at the University of Bordeaux, Novaptech currently has 9 employees and plans to recruit a further 5 by the end of 2025. Specialising in the development of aptamers, Novaptech stands out as the only French company to master this breakthrough technology. Aptamers, which can replace antibodies in all analytical, diagnostic and therapeutic applications, are at the heart of Novaptech’s strategy. The company is initially focusing on the development of biosensors for real-time detection of contaminants in the agri-food industry, such as pesticides, micropollutants and endocrine disruptors, in response to the need for rapid, simple and decentralised testing. In line with the objectives of the Neo Terra strategic roadmap drawn up by the Conseil Régional de Nouvelle-Aquitaine for the ecological and energy transition, Novaptech recently validated its first laboratory-scale aptasensor.  The Conseil Régional de Nouvelle-Aquitaine has supported Novaptech since its creation. Once again this year, the Region has supported the company in strengthening its export strategy, particularly in Asia. The inauguration of these brand new premises marks an important step for Novaptech, consolidating its role as a leader in the biotechnology sector and its commitment to innovation and the protection of public health. For more details, read the full press release from the Cabinet of President Alain Rousset here (in French).

Novaptech at RICT 2024 in Bordeaux on July 3-5 !

We will be present at the 58th International Conference on Medicinal Chemistry. This year the meeting will be dedicated to « Interfacing Chemical Biology and Drug Discovery ».  https://www.rict2024.org/ Discover how aptamers enable new therapeutic treatments, including the targeted delivery of drugs and more. Drop by booth # 30 and meet our CSO, Dr J.-J. Toulmé, discuss the latest aptamer developments and how they could bring a new perspective to your particular needs. See you there! Or contact him at jj.toulme@novaptech.com

📣ECHOS is talking about us!📣

ECHOS is talking about us ! https://www.echos-judiciaires.com/actualites/novaptech-le-potentiel-insoupconne-des-aptameres/ 

📣AGRO Media is talking about us!📣

AGRO Media is talking about us! Biotechnologie : Novaptech inaugure de nouveaux locaux pour renforcer la détection de contaminants agroalimentaires

📣Sud Ouest is talking about us!📣

Sud Ouest is talking about us! Article in French. https://www.sudouest.fr/economie/novaptech-la-start-up-qui-traque-pathogenes-agents-chimiques-ou-biologiques-dans-l-air-l-eau-et-les-aliments-19964889.php?csnt=18fe70c0a37

🎉A major milestone for Novaptech!🚀

Last Friday, we had the pleasure of inaugurating our brand new 450 m2 premises in Gradignan, in the presence of our partners, associates, staff and friends. Many thanks to Mr Alain Rousset, President of the Nouvelle-Aquitaine Region, and Mr Michel Labardin, Mayor of Gradignan, for honouring this event with their presence. Over the past 8 years, Novaptech has been engaged to pursue its ambition to innovate in the field of aptamers. Thanks to the support of our long-standing partners, the University of Bordeaux, Inserm, Adera, the Regional Government, Unitec, Aquiti, Bpifrance, the experts we are partnering with, our shareholders and the commitment of our teams, we are the only French company among the 20 biotechs worldwide expert in the aptamer field. Proud to be contributing to the growth of the biotech sector in the Nouvelle-Aquitaine region and to the international recognition of French excellence, we have invested over €2 millions in R&D (Research and Development) since our creation. Our new state-of-the-art laboratories will enable us to accelerate the development of innovative solutions in the health, agri-food and environment sectors. Thank you to all our partners for supporting us in this great adventure!

Novaptech is coming to Barcelona!BIO-Europe Spring 2024

Our team will be in Barcelona from 18 March to 20 March 2024. Book a meeting with our two co-founders, Marine Laville, President and Chief Executive Officer, and Jean-Jacques Toulmé, Chief Scientific Officer, to discover how Novaptech can revolutionize your scientific approach. We are eager to discuss how Novaptech, a specialist in custom aptamers, can support your projects with solutions for: – Custom aptamer selection & characterization – Aptamer optimization & aptamer-based assay development – Structure-switching aptamers for multiplex assays Get in touch today to book your on-site meeting with the team and start building towards your next breakthrough.  Link to event: https://informaconnect.com/bioeurope-spring/

Novaptech moved to brand new facilities.

We are happy to announce that Novaptech moved to brand new facilities. Our head quarter and labs are now located in Gradignan (nearby the campus of the University of Bordeaux). Our 450 m2 laboratory offers bright and functional space for automated selection, bioinformatics analysis and biophysical characterization of aptamers.

Novaptech at the Bio-Europe Spring

Novaptech will participate in Bio-Europe Spring in Basel from March 20 to 22, 2023 and its digital version from March 28 to 30, 2023.  Looking for new therapeutic agents, innovative diagnostic or analytical tools? Meet Novaptech, at Bio-Europe Spring either in Basel or online, the expert company for selection and optimization of aptamers and the design of aptamer-based assays and devices.

Novaswitch by Novaptech

Novaptech selects, characterizes, optimizes and functionalizes aptamers for your project, whatever the type of target. Following the evaluation of the feasibility of your project, we run several positive and negative steps of selection under conditions compatible with your assay. The selection of NOVAswitches is carried out with targets FREE in solution. No need to synthesize analogs for immobilization on a solid support. No risk to generate aptamers against the linker. The target molecule used for NOVAswitch selection is the same as the one to be detected in your assay. The process for NOVAswitch selection relies on a structural change occurring upon binding to the target. This reduces the risk of selecting sequences binding to the support. The structural change is secondarily exploited for signalling the presence of the target molecule. This makes easier the design of aptamer-based assays and aptasensors. Just mix NOVAswitch and your sample and read! Novaptech offers different formats for optical signalling with NOVAswitches.